Silco Pharmaceuticals Limited

Un-Audited Financial Statements (First Quarter)

For the period from 1st July 2026 to 30 September 2026

Silco Pharmaceuticals Limited
Statement of Financial Position
As at September 30, 2026

Particulars	Notes	Amount in Taka	
		30 Sept. 2026	30 June 2026
Assets:			
Non Current Assets		**1,730,443,497**	**1,737,919,625**
Property, Plant and Equipment	**3.00**	1,554,513,438	1,568,351,908
Right of Use Assets	**4.00**	10,354,029	-
Capital Work-in-Progress	**5.00**	165,576,030	169,567,717
Current Assets		**1,061,857,913**	**1,033,113,387**
Inventories	**6.00**	463,575,733	454,394,131
Trade and Other Receivables	**7.00**	453,634,392	438,245,534
Advances, Deposits and Prepayments	**8.00**	127,916,601	122,953,674
Cash and Cash Equivalents	**9.00**	16,731,187	17,520,047
Total Assets		**2,792,301,410**	**2,771,033,012**
Shareholder's Equity and Liabilities:			
Shareholder's Equity		**2,424,101,866**	**2,416,405,049**
Share Capital	**10.00**	1,038,070,000	1,038,070,000
Retained Earnings	**11.00**	1,386,031,866	1,378,335,049
Non-Current Liabilities		**163,681,445**	**155,701,183**
Lease Liabilities (Non Current Portion)	**12.00**	7,797,019	-
Deferred Tax Liabilities	**13.00**	155,884,426	155,701,183
Current Liabilities		**204,518,099**	**198,926,780**
Trade and Other Payable	**14.00**	9,261,482	9,499,290
Lease Liabilities (Current Portion)		2,647,114	-
Payable to IPO Applicants	**15.00**	184,389	184,389
Provision for Expenses	**16.00**	5,762,288	5,233,792
Liabilities for contribution to WPPF	**17.00**	2,643,928	2,143,282
Dividend Payables (Unclaimed)	**18.00**	774,301	774,301
Provision for income tax	**19.00**	183,244,597	181,091,725
Total Shareholder's Equity and Liabilities		**2,792,301,410**	**2,771,033,012**
Net Asset Value (NAV) per Share	**28.00**	**23.35**	**23.28**

The annexed notes form an integral part of these financial statements.

Chairman | Managing Director | Director | Company Secretary | Chief Financial Officer

Signed as per our separate report on same date.

Place: Dhaka
Date: 12 November 2026

Silco Pharmaceuticals Limited
Statement of Profit or Loss and other Comprehensive Income
For the period ended September 30, 2026

Particulars	Notes	Amount in Taka	
		01 July 2026 to 30 Sept. 2026	01 July 2025 to 30 Sept. 2025
Turnover	**20.00**	83,761,050	116,046,808
Less: Cost of Goods Sold	**21.00**	57,178,106	76,571,065
Gross Profit /(Loss)		**26,582,944**	**39,475,743**
Less: Operating Expenses	**22.00**	15,859,808	17,360,200
Profit from Operation		**10,723,137**	**22,115,543**
Less: Financial Expenses	**23.00**	11,351	41,823
Less: Financial Expenses (Lease)	**24.00**	198,229	99,121
Non-operation Income	**25.00**	20,020	145,500
Profit before Contribution to WPPF		**10,533,577**	**22,120,099**
Less: Workers' Profit Participation/Welfare Fund (WPP	**17.01**	500,646	1,046,409
Profit before Income Tax		**10,032,931**	**21,073,690**
Less: Provision for Income Tax	**26.00**	**2,336,115**	**4,741,580**
Current Tax	**26.01**	2,152,872	4,548,946
Deferred Tax	**26.02**	183,242	192,634
Net Profit/(Loss) after Tax (Transferred to Retained Earning)		**7,696,817**	**16,332,109**
Other Comprehensive Income:			
Unrealized Gain/(Loss) on Investment		-	-
Total Comprehenshive income		**7,696,817**	**16,332,109**
Earnings per Share (EPS)	**27.00**	**0.07**	**0.16**

The annexed notes form an integral part of these financial statements.

নাইম হক (ভন)

Chairman | Managing Director | Director | Company Secretary | Chief Financial Officer

Signed as per our separate report on same date.

Place: Dhaka
Date: 12 November 2026

Silco Pharmaceuticals Limited

Statement of Changes in Equity

For the period ended September 30, 2026

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Amount in Taka
Balance as at July 01, 2026	1,038,070,000	-	1,378,335,049	2,416,405,049
Net Profit/(Loss) during the period	-	-	7,696,817	7,696,817
Balance as on September 30, 2026	**1,038,070,000**	**-**	**1,386,031,866**	**2,424,101,866**

Statement of Changes in Equity

For the period ended September 30, 2025

Particulars	Ordinary Share Capital	Unrealized Gain/Loss on Marketable Securities	Retained Earnings	Amount in Taka
Balance as at July 01, 2025	1,038,070,000	-	1,351,812,499	2,389,882,498
Net Profit/(Loss) during the period	-	-	16,332,109	16,332,109
Balance as on September 30, 2025	**1,038,070,000**	**-**	**1,368,144,608**	**2,406,214,607**

Chairman | Managing Director | Director | Company Secretary | Chief Financial Officer

Place: Dhaka
Date: 12 November 2026

Silco Pharmaceuticals Limited
Statement of Cash Flows
For the period ended September 30, 2026

Particulars	Notes	Amount in Taka	
		01 July 2026 to 30 Sept. 2026	01 July 2025 to 30 Sept. 2025
A. Cash Flows from Operating Activities			
Cash received from Customers	32.00	68,372,192	99,069,712
Cash received from Non-operating income		20,020	145,500
Cash Paid to Suppliers	33.00	(42,143,443)	(43,677,392)
Cash Paid to Employees	34.00	(14,680,436)	(16,945,821)
Cash Paid to Others	35.00	(7,741,158)	(8,579,085)
Financial Expenses		(11,351)	(41,823)
Income Tax Paid		(1,554,520)	(1,624,562)
Net cash flows from operating activities		**2,261,304**	**28,346,529**
B. Cash Flows from Investing Activities			
Acquisition of Property, Plant & Equipment		(2,000,765)	-
Cash Payment for Capital Work-in-Progress		-	(21,386,335)
Gain/(Loss) on Investment		-	-
Investment in Share			-
Net cash used in investing activities		**(2,000,765)**	**(21,386,335)**
C. Cash Flows from Financing Activities			
Refund to IPO Applicants (Bank Charge)		-	-
Financial Expenses (Lease)		(198,229)	(99,121)
Principle payment (Lease)		(851,171)	(1,207,394)
Cash dividend paid		-	(12,535)
Net Cash used for financing activities		**(1,049,400)**	**(1,319,050)**
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)		**(788,861)**	**5,641,144**
E. Cash and Cash Equivalents at the beginning of the period		**17,520,047**	**26,261,323**
F. Cash and Cash Equivalents at the end of the period (D+E)		**16,731,187**	**31,902,467**
Net Operating Cash Flows Per Share (NOCFPS)	29.00	**0.02**	**0.27**

Chairman | Managing Director | Director | Company Secretary | Chief Financial Officer

Place: Dhaka
Date: 12 November 2026